Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 4/2013

Open Access 01-10-2013 | Gynecologic Oncology

Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study

Authors: Leszek Gottwald, Janusz Piekarski, Robert Kubiak, Jarosław Szwalski, Grażyna Pasz-Walczak, Piotr Sęk, Michał Spych, Jacek Suzin, Wiesław Tyliński, Arkadiusz Jeziorski

Published in: Archives of Gynecology and Obstetrics | Issue 4/2013

Login to get access

Abstract

Purpose

To evaluate the membrane expression of DR4, DR5, DcR1 and DcR2 in the normal endometrium (NE), atypical endometrial hyperplasia (AEH) and endometrioid adenocarcinoma (EAC).

Methods

The study comprised 197 patients: 20 NE, 18 AEH and 159 EAC. Tissue microarrays were constructed. Membrane expression of DR4, DR5, DcR1 and DcR2 was examined and presented as total score (TS).

Results

In EAC, the membrane expression of DR4, DR5 and DcR2 was less common compared to NE (p < 0.001; p < 0.001; p = 0.018) and AEH (p < 0.001; p < 0.001; p = 0.004). In EAC the membrane expression of DcR1 did not differ when compared to NE (p = 0.055) and AEH (p = 0.173). A strong correlation was found between the type of endometrial tissue (NE/AEH/EAC) and the TS of DR4 (p < 0.001), DR5 (p < 0.001), DcR1 (p = 0.033) and DcR2 (p < 0.001). In EAC, the TS of DR4, DR5, DcR1 and DcR2 was not related to grading and staging. In EAC, the membrane expression of DR5, but not DR4, DcR1 and DcR2, was related to better disease-free survival (DFS). The overall survival (OS) was not related to membrane TRAIL receptors expression.

Conclusions

The membrane expression of the receptors for TRAIL DR4, DR5, DcR1 and DcR2 is greater in NE than EAC. The level of membrane staining of the receptors in EAC is not dependent on grading and staging. In EAC patients, membrane expression of DR4, DR5, DcR1 and DcR2 are not independent predictors of survival.
Literature
1.
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–682PubMedCrossRef
2.
Wajant H, Pfizenmaier K, Scheurich P (2002) TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7:449–459PubMedCrossRef
3.
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818–827PubMedCrossRef
4.
Lee YJ, Heurta-Yepez S, Vega M, Baritaki S, Spandidos DA, Bonavida B (2007) The no TRAIL to yes TRAIL in cancer therapy (review). Int J Oncol 31:685–691PubMed
5.
Sadarangani A, Kato S, Espinoza N, Lange S, Llados C, Espinosa M, Villalon M, Lipkowitz S, Cuello M, Owen GL (2007) TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis 12:73–85PubMedCrossRef
6.
7.
Newsom-Davis T, Prieske S, Walczak H (2009) Is TRAIL the holy grail of cancer therapy? Apoptosis 14:607–623PubMedCrossRef
8.
Frank S, Köhler U, Schackert G, Schackert H (1999) Expression of TRAIL and its receptors in human brain tumors. Biochem Biophys Res Comm 257:454–459PubMedCrossRef
9.
Koornstra JJ, Kleibeuker JH, van Geelen C, Rijcken F, Hollema H, de Vries EG, de Jong S (2003) Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas and carcinomas. J Pathol 200:327–335PubMedCrossRef
10.
Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, Hollema H, de Jong S (2004) Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 52:821–831PubMedCrossRef
11.
Younes M, Georgakis GV, Rahmani M, Beer D, Younes A (2006) Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur J Cancer 42:542–547PubMedCrossRef
12.
Ganten TM, Sykora J, Koschny R, Batke E, Aulmann S, Mansmann U, Stremmel W, Sinn HP, Walczak H (2009) Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med 87:995–1007PubMedCrossRef
13.
Yoldas B, Ozer C, Ozen O, Canpolat C, Dogan I, Griffith T, San lioglu S, Ozluoglu LN (2011) Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck 33:1278–1284PubMedCrossRef
14.
Kendrick JE, Estes JM, Straughn JM Jr, Alvarez RD, Buchsbaum DJ (2007) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecol Oncol 106:614–621PubMedCrossRef
15.
Tarragona J, Llecha N, Santacana M, Lopez S, Gatius S, Llobet D, Dolcet X, Palomar-Asenjo V, Gonzalez-Tallada FJ, Matias-Guiu X (2010) DcR1 expression in endometrial carcinomas. Virchows Arch 456:39–44PubMedCrossRef
16.
Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynaecol Obstet 105:103–104PubMedCrossRef
17.
Silverberg S, Kurman R, Nogales F, Mutter G, Kubik-Huch R, Tavassoli FA (2003) Epithelial tumours and related lesions. In: Tavassoli FA, Devilee P (eds) World health organization classification of tumors. Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, pp 221–232
18.
Chen W, Foran DJ (2006) Advances in cancer tissue microarray technology: towards improved understanding and diagnostics. Anal Chim Acta 564:74–81PubMedCrossRef
19.
Takikita M, Chung JY, Hewitt SM (2007) Tissue microarrays enabling high-throughput molecular pathology. Curr Opin Biotechnol 18:318–325PubMedCrossRef
20.
Gulmann C, O`Grady A (2003) Tissue microarrays: an overview. Curr Diagn Pathol 9:149–154CrossRef
21.
Gottwald L, Sek P, Piekarski J, Pasz-Walczak G, Kubiak R, Szwalski J, Spych M, Suzin J, Tylinski W, Topczewska-Tylinska K, Jeziorski A (2012) Construction of a tissue microarray with 2 mm-size cores in endometrioid endometrial cancer—factors affecting quality of the recipient block. Biotech Histochem 87:512–518PubMedCrossRef
22.
Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O (2006) Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26:7046–7055PubMedCrossRef
23.
Davidovich IA, Levenson AS, Levenson (Chernokhvostov) VV (2004) Overexpression of DcR1 and survivin in genetically modified cells with pleiotropic drug resistance. Cancer Lett 211:189–197PubMedCrossRef
24.
Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M (2004) Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines in overcome by co-treatment with cytotoxic drugs. Gynecol Oncol 94:107–114PubMedCrossRef
25.
Li Y, Jin X, Li J, Jin X, Yu J, Sun X, Chu Y, Xu C, Li X, Wang X, Kakehi Y, Wu X (2012) Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis. Urology 79:968.e7–968.e15CrossRef
26.
Ozawa F, Friess H, Kleeff H, Xu ZW, Zimmermann A, Sheikh MS, Buchler MW (2001) Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 163:71–81PubMedCrossRef
27.
Koksal IT, Sanlioglu AD, Karacay B, Griffith TS, Sanlioglu S (2008) Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 26:158–165PubMedCrossRef
28.
Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Screaton G, Hersey P (2006) Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol 37:1286–1294PubMedCrossRef
29.
Wu X, Hui KM (2004) Induction of potent TRAIL-mediated tumoricidal activity by hFLEX/Furin/TRAIL recombinant DNA construct. Mol Ther 9:674–681PubMedCrossRef
30.
Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X (2010) The multikinase inhibitor sorafenib induces apoptosis and sensitizes endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 46:836–850PubMedCrossRef
31.
Moxley KM, Chengedza S, Mangiaracina D (2009) Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: the search for sensitizing agents. Gynecol Oncol 115:438–442PubMedCrossRef
32.
Straughn JM Jr, Oliver PG, Zhou T, Wang W, Alvarez RD, Grizzle WE, Buchsbaum DJ (2006) Anti-tumor activity of TRA-8-anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 101:46–54PubMedCrossRef
33.
Jo M, Kim TH, Seol DW, Espen JE, Dorko K, Billiar TR, Strom SC (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564–567PubMedCrossRef
34.
Volkmann X, Fischer U, Bahr MJ, Ott M, Lehner F, Macfarlane M, Cohen GM, Manns MP, Schulze-Osthoff K, Bantel H (2007) Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 46:1498–1508PubMedCrossRef
Metadata
Title
Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study
Authors
Leszek Gottwald
Janusz Piekarski
Robert Kubiak
Jarosław Szwalski
Grażyna Pasz-Walczak
Piotr Sęk
Michał Spych
Jacek Suzin
Wiesław Tyliński
Arkadiusz Jeziorski
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 4/2013
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-013-2840-x

Other articles of this Issue 4/2013

Archives of Gynecology and Obstetrics 4/2013 Go to the issue

Reproductive Medicine

Reproductive performance in the next pregnancy for nulliparous women with history of first trimester spontaneous abortion

Gynecologic Oncology

Uterine sarcoma-current management and experience from a regional cancer centre in North India

General Gynecology

A pilot study of Foley’s catheter balloon for prevention of intrauterine adhesions following breach of uterine cavity in complex myoma surgery

General Gynecology

Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?

Maternal-Fetal Medicine

Sexual function after childbirth by the mode of delivery: a prospective study

Maternal-Fetal Medicine

Proteomic analysis of preterm premature rupture of membranes in placental tissue